佰仁医疗: 佰仁医疗第三届监事会第七次会议决议公告

Core Viewpoint - The company’s supervisory board has approved adjustments to its 2020 restricted stock incentive plan, including changes to the grant price and the status of unvested shares, ensuring compliance with relevant laws and regulations [1][2][3][4] Meeting Details - The third supervisory board meeting was held on June 13, 2025, with all three supervisors present, confirming the legality and validity of the meeting procedures [1] Resolutions Passed - The grant price for the 2020 restricted stock incentive plan was adjusted from 15.91 CNY per share to 15.11 CNY per share, with unanimous approval [2] - The board agreed to cancel a portion of the granted but unvested restricted stocks, which aligns with legal and regulatory requirements [2] - The fifth vesting period of the initial grant under the 2020 restricted stock incentive plan was confirmed to meet the vesting conditions, allowing 65 participants to vest 267,772 shares [3] - The third vesting period of the reserved grant under the 2020 restricted stock incentive plan was also confirmed to meet the vesting conditions, allowing 44 participants to vest 85,213 shares [4]